Drugs / AD-218
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05400317 | Jul 2022 → Mar 2026 overdue | hyperlipidemia, combined, 2 | Addpharma Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-218 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05400317 ↗ |
| Route | Oral | “PO, Once daily(QD), 12weeks” NCT05400317 ↗ |